Development and characterization of transdermal therapeutics system of tramadol hydrochloride

Main Article Content

Anil J Shinde
Kevin C Garala
Harinath N More


The present work was designed to develop suitable transdermal matrix patches of tramadol hydrochloride, a non-steroidal anti-inflammatory drug, using hydroxy propyl methyl cellulose (HPMC), Eudragit RL-100 and Eudragit RS-100 with
triethyl citrate as a plasticizer and dimethyl sulfoxide (DMSO) as a penetration enhancer. Different batches developed using Eudragit RL-100 : HPMC and Eudragit RS-100 : HPMC in ratio of 2 : 8, 4 : 6, 6 : 4, and 8 : 2. Drug - excipients interaction study was further carried out using Fourier transform infrared (FTIR) spectroscopic technique. Physical evaluation was performed such as moisture content, moisture uptake, tensile strength, flatness, and folding endurance. In vitro diffusion studies were performed using cellulose acetate membrane (pore size 0.45 μ) in a Franz’s diffusion cell.The concentration of
diffused drug was measured using UV-visible spectrophotometer (Jasco V-530) at λmax 275 nm.The batch containing EudragitRL-100 : HPMC (8 : 2) showed 79.65% release within 12 h and batch containing Eudragit RL-100 : HPMC (2 : 8) showed only 58.30% release in 12 h. This is because that the Eudragit produce crystallization free patch.


Download data is not yet available.

Article Details

How to Cite
Shinde, A. J., Garala, K. C., & More, H. N. (2014). Development and characterization of transdermal therapeutics system of tramadol hydrochloride. Asian Journal of Pharmaceutics (AJP), 2(4).


Benson HA. Transdermal drug delivery: Penetration enhancement

techniques. Curr Drug Deliv 2005;2:23-33.

Cross SE Robert S. Targeting local tissues by transdermal application:

Understanding drug physicochemical properties that best exploit protein

binding and blood flow effects. Drug Dev Res 1999;46:309-15.

Finnin BC. Transdermal drug delivery: What to expect in the near future,

business briefing. Pharmatech 2003;:192-3.

Kumar R, Philip A. Modified transdermal technologies: Breaking

the barriers of drug permeation via the skin. Trop J Pharma Res


Martin RJ, Denyer SP, Hadgraft J. Skin metabolism of topically applied

compounds. Int J Pharm 1987;39:23-32.

Denyer SP, Guy RH, Hadgraft J, Hugo WB. The microbial degradation

of topically applied drugs. Int J Pharm 1985;26:89-97.

Pannatier A, Jenner P, Testa B, Etter JC. The skin as a drug metabolizing

organ. Drug Metab Rev 1978;8:319-43.

Williams AC, Barry BW. Skin absorption enhancers. Crit Rev Therap

Drug Carrier Syst 1992;9:305-53.

Tojo K. Design and calibration of in vitro permeation apparatus. In:

Chien YW, editor. Transdermal controlled systemic medications. New

York: Marcel Dekker; 1987. p. 127-58.

Moffat AC. Clark’s isolation and identification of drugs. 2nd ed. London:

The Pharmceutical Society of Great Britain; 1986. p. 1033-4.

Mukherjee B, Mahapatra S, Gupta R, Patra B, Tiwari A, Arora P. A

comparison between povidone-ethylcellulose and povidone-eudragit

transdermal dexamethasone matrix patches based on in vitro skin

permeation. Eur J Pharma Biopharma 2005;59:475-83.

Arora P, Mukherjee P. Design, development, physicochemical, and

in vitro and in vivo evaluation of transdermal patches containing

diclofenac diethylammonium salt. J Pharm Sci 2002;91:2076-89.

Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone-ethyl cellulose

matrices. Drug Dev Ind Pharm 2003;29:1-7.

Ubaidulla U, Reddy MV, Ruckmani K. Transdermal therapeutic system

of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro

and in vivo characteristics. AAPS PharmSciTech 2007;8:E1-8.